Do you have benign prostatic hyperplasia (BPH)?
If so, you may be eligible to participate in this research program
Managing your benign prostatic hyperplasia (BPH) alone may not be enough.
If you are on BPH therapy and visiting the bathroom frequently, you may have an overactive bladder (OAB).
The immediate need to ‘go’ interrupts your day and night – and it may not be caused by your BPH.
- Do you have to use the bathroom at least 8 times a day?
- Do you still wake up 2 or more times each night to use the bathroom?
- Do you experience a need to use the bathroom immediately (urinary urgency)?
If these symptoms disrupt your day and night, you may also have a condition called OAB.
Can I take part?
To determine whether you are eligible to take part in the COURAGE Study, you first need to fill out the form or call us. Then, you will be invited to visit our study center to undergo medical tests and assessments. If eligible, you will be asked to return to the study center 10 more times to undergo further tests. You will be asked to take either the investigational drug or placebo every day for 26 weeks.
Research participants will receive $100 for each office visit after they qualify for the program.
About the COURAGE Study
A clinical research study is testing the safety and effectiveness of an investigational drug in men on benign prostatic hyperplasia (BPH) therapy experiencing overactive bladder (OAB) symptoms. The investigational drug is compared with a placebo. A placebo looks exactly like the investigational drug but contains no active medication. Over 1,000 participants in over 135 study centers across North America and Europe are expected to take part in the COURAGE Study.
OAB is highly prevalent and affects approximately 16% of the population in the United States and Europe. Prevalence increases with age, affecting approximately one third of people 75 years and older [Stewart, 2003; Milsom, 2001]. Despite similar prevalence between the sexes and growing clinical trial evidence that men benefit from pharmacotherapy, men are less likely to use treatment for OAB [Goldman, 2016].
What happens at the end of the study?
At the end of 26 weeks, you may be able to join a 28-week extension period, during which you will receive the investigational drug only. If you do not join the extension study, you will receive a telephone call from the study team 3 weeks after your last dose of the study drug to check on your overall health and well-being.